Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is
associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy.
Neo-adjuvant immunotherapy is a promising additional treatment modality aiming at increasing
local control and better tackling micrometastases at the time of radical local treatment.
Radiotherapy is thought to act synergistically with immunotherapy through release of tumor
antigens and modulation of the local immune microenvironment in favor of a better
antigen-presentation and (systemic) anti-tumor immune response (abscopal effect).
The aim of the proposed SAKK 16/18 trial is to evaluate the efficacy and safety of adding
immune-modulatory radiotherapy to the SAKK 16/14 treatment regimen by combining neo-adjuvant
radio-immunotherapy. Due to the lack of evidence for an optimal radiotherapy regimen for an
"in-situ vaccination" effect three different radiotherapy regimens will be tested.